Email this article Effects of combined treatment with rosiglitazone and NPH insulin on carbohydrate metabolism in patients with type 2 diabetes mellitus
- Authors: Kandalintseva OA1, Ametov AS1, Kandalintseva OA1, Ametov AS1
-
Affiliations:
- ГОУ ДПО РМАПО Росздрава, Москва
- Issue: Vol 80, No 12 (2008)
- Pages: 40-44
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30253
- ID: 30253
Cite item
Full Text
Abstract
Aim. To study efficacy and safety of rosiglitazone + NPH insulin combined treatment in patients with type 2 diabetes mellitus (DM).
Material and methods. The trial included 43 patients with DM aged 44-75 on NPH insulin. The patients were divided into two groups. The study group received NPH insulin + a single morning dose of 4 mg/day rosiglitazone, the control group received NPH insulin only. The treatment lasted 24 weeks.
Results. 24-week therapy in the study group lowered HbA1c from 8.16 ± 0.23 to 6.82 ± 0.18% (p < 0.05), fasting glycemia - from 9.68 ± 0.48 to 6.4 ± 0.32 mmol/l, postprandial glycemia - from 12.3 ± 0.44 to 8.4 ± 0.56 mmol/l, HOMA-IR index - from 7.65 ± 1.12 to 4.26 ± 0.59. In group 2 HbA1c - from 7.84 ± 0.15 to 7.49 ± 0.17 (p < 0.05), from 9.21 ± 0.65 to 8.38 ± 0.50 mmol/l, 11.92 ± 0.53 to 9.97 ± 0.45 mmol/l, 6.77 ± 0.79 to 5.73 ± 0.63. The combined treatment produced positive changes in lipid metabolism: total cholesterol decreased from 6.37 ± 0.36 to 5.67 ± 0.32 mmol/l (p < 0.005), TG - from 2.46 ± 0.64 mmol/l to 1.82 ± 0.46 mmol/l (p < 0.005), LDLP - from 3.99 ± 0.40 to 3.58 ± 0.37 mmol/l. Need in insulin diminished by 10%.
Conclusion. Treatment results showed that administration of rosiglitazone in combination with NPH insulin has a good safety and tolerance profile in type 2 DM patients.
Material and methods. The trial included 43 patients with DM aged 44-75 on NPH insulin. The patients were divided into two groups. The study group received NPH insulin + a single morning dose of 4 mg/day rosiglitazone, the control group received NPH insulin only. The treatment lasted 24 weeks.
Results. 24-week therapy in the study group lowered HbA1c from 8.16 ± 0.23 to 6.82 ± 0.18% (p < 0.05), fasting glycemia - from 9.68 ± 0.48 to 6.4 ± 0.32 mmol/l, postprandial glycemia - from 12.3 ± 0.44 to 8.4 ± 0.56 mmol/l, HOMA-IR index - from 7.65 ± 1.12 to 4.26 ± 0.59. In group 2 HbA1c - from 7.84 ± 0.15 to 7.49 ± 0.17 (p < 0.05), from 9.21 ± 0.65 to 8.38 ± 0.50 mmol/l, 11.92 ± 0.53 to 9.97 ± 0.45 mmol/l, 6.77 ± 0.79 to 5.73 ± 0.63. The combined treatment produced positive changes in lipid metabolism: total cholesterol decreased from 6.37 ± 0.36 to 5.67 ± 0.32 mmol/l (p < 0.005), TG - from 2.46 ± 0.64 mmol/l to 1.82 ± 0.46 mmol/l (p < 0.005), LDLP - from 3.99 ± 0.40 to 3.58 ± 0.37 mmol/l. Need in insulin diminished by 10%.
Conclusion. Treatment results showed that administration of rosiglitazone in combination with NPH insulin has a good safety and tolerance profile in type 2 DM patients.
Keywords
About the authors
O A Kandalintseva
ГОУ ДПО РМАПО Росздрава, МоскваКафедра эндокринологии и диабетологии с курсом эндокринной хирургии; ГОУ ДПО РМАПО Росздрава, Москва
A S Ametov
ГОУ ДПО РМАПО Росздрава, МоскваКафедра эндокринологии и диабетологии с курсом эндокринной хирургии; ГОУ ДПО РМАПО Росздрава, Москва
O A Kandalintseva
A S Ametov
References
- International Diabetes Federation. Diabetes and cardiovascular disease; time to act. Brussels: International Diabetes Federation; 2001.
- Аметов A. C. Нарушения жизненного цикла и функции β-клеток поджелудочной железы: центральное звено патогенеза сахарного диабета 2 типа: Учеб. пособие. М.; 2002.
- Анциферов М. Б., Дорофеева Л. Г. Авандия (Росиглитазон) - современный инсулиновый сенситайзер для коррекции инсулинорезистентности при сахарном диабете типа 2. Фарматека 2005; 12: 16-23.
- Fonseca V. A., Biswas N., Salzman A. Once-daily rosiglitazone in combination with metformin effectively reduced hyperglycemia in patients with type 2 diabetes. Diabetes 1999; 48: A100.
- Widlansky M. E., Gokce N., Keaney J. F. Jr. et al. The clinical implications of endothelial dysfunction. J. Am. Coll. Cardiol. 2003; 42: 1149-1160.
- Leonard T. B., Bakst A., Warsi G. et al. Rosiglitazone may reduce insulin resistance related cardiovascular disease risk in patients with type 2 diabetes. Diabetes 2001; 50 (2): 441.
- Parulkar A. A., Pendergrass M. L., Granda-Ayala R. et al. Nonhypoglycemic effects of thiazolidinediones. Ann. Intern. Med. 2001; 134: 61-71.
- Nissen S. E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from the cardiovascular causes. N. Engl. J. Med. 2007; 356: 2457-2471.
- Kahn S. E., Haffner S. M., Heise M. A. et al, for the ADOPT study groupe. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 2006; 355: 2427- 2443.
- The DREAM (Diabetes reduction assessment with ramipril and rosiglitazone medication) trial investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006; 368: 1096-1105.
- Home P. D., Phil D., Stuart J. et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N. Engl. J. Med. 2007; 357: 1-11.
- Matthews D. R., Hosker J. P., Rudenski A. S. et al. Homeostasis model assessment: insulin resistance and - cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
Supplementary files
